What Oasis Tears Plus Treats: Main Uses and Benefits

The therapeutic focus of Oasis Tears Plus is relevant for easing symptoms related to physical discomfort and irritative states of the eye. As an ophthalmic lubricant, it is commonly used across conditions presenting with acute episodes of dryness.

The solution helps address symptom clusters that may become intense or disruptive, including the sensations of burning, stinging, grittiness, and overall eye irritation. It is relevant for easing symptoms that interfere with daily comfort, such as the persistent feeling of a foreign body sensation. It contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.

It is commonly used when supportive symptom management is appropriate for individuals with sensitive eyes or those dealing with recurrent or episodic manifestations. It is often used during phases when symptoms become more noticeable due to environmental stress (like wind or air conditioning) or prolonged visual tasks.

“The product contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Supports Easing Burning and Grittiness

Regulatory References

1. NIH DailyMed overview of Oasis Tears Plus

Who Can and Cannot Use Oasis Tears Plus?

The eligibility criteria for using Oasis Tears Plus are defined by its classification as an Over-The-Counter (OTC) ophthalmic lubricant. Regulatory labeling strictly dictates the populations who can and must not use this preservative-free solution.

---

Official Population Eligibility Status

Category	Eligibility Rule
Absolute Contraindication	Use is contraindicated if the patient is known to have a sensitivity or allergy to any ingredient in the product, including Glycerin and Sodium hyaluronate.
Standard Use Population	The product is generally intended for adult use for the temporary relief of dry eye symptoms, consistent with its status as a HUMAN OTC DRUG.
Pediatric Use	Use in the pediatric population is not established in the official labeling. The label advises keeping the product out of reach of children.
Pregnancy/Lactation	No specific restrictions or formal recommendations regarding use during pregnancy or lactation are documented in the official labeling.
Organ Function	No restrictions are formally documented based on systemic conditions such as hepatic or renal impairment, consistent with a topical, non-systemic product.

---

Summary of Eligibility Constraints

The most critical restriction is the absolute prohibition for individuals with a history of hypersensitivity to any component of the solution. Beyond this, the regulatory framework permits use by the general adult population. Use in children is not explicitly established, representing a population for whom use is not documented in the current regulatory profile.

Interactions with other medicines and products

The official regulatory profile for Oasis Tears Plus, an ophthalmic lubricant, is characterized by the absence of systemic interaction concerns. Because this product is administered topically to the eye, the active ingredients, Glycerin and Sodium hyaluronate, exhibit minimal to negligible systemic absorption. This local application prevents the development of systemic drug-drug interactions.

Regulatory labels do not cite formal interaction studies for systemic medicines, nor do they document interactions involving metabolic enzymes (like CYP) or drug transporters. Formal contraindicated combinations with systemic medicinal products are not listed.

Documented Interaction Patterns

The interaction profile is instead governed by Administration-Timing Constraints related to local eye therapies. The primary interaction requirement is a Timing-Separation rule, classified as an Administration-Timing Interaction:

Interaction Category	Official Constraint/Requirement
Systemic Drug-Drug	None documented (due to minimal systemic exposure).
Metabolic/Transporter	None documented.
Timing Requirement	Must be separated from other ophthalmic preparations.
Food/Alcohol/Supplements	None documented.

This required separation ensures that co-administration does not result in a physical interference that could dilute or wash out a subsequently applied topical eye medication, thereby preserving the local efficacy of both preparations.

The mechanism of action of Oasis Tears Plus is purely physicochemical and cytoprotective, operating through the properties of its active and inactive demulcent components on the ocular surface.

The formulation contains Glycerin, a demulcent and humectant, which functions by increasing the hydration potential of the applied solution. This forms a protective, hydrophilic film over the corneal and conjunctival epithelia. The film establishes a localized, lowered-osmolarity microenvironment at the ocular surface, counteracting the hyperosmolarity characteristic of a compromised tear film.

In addition, the formulation incorporates Sodium Hyaluronate, a high-molecular-weight glycosaminoglycan. Sodium Hyaluronate acts as a viscoadaptive polymer, increasing the shear viscosity of the solution upon instillation. This enhanced viscosity prolongs the residence time of the solution on the ocular surface, enabling extended surface coating. The mucoadhesive properties of sodium hyaluronate further contribute to the stabilization and thickening of the precorneal tear film layer, leading to the sustained physiological effect of corneal wetting and friction reduction.

How to use Oasis Tears Plus: Administration Guidelines

Oasis Tears Plus is an over-the-counter (OTC) ophthalmic preparation intended for topical ocular administration to temporarily relieve burning, irritation, and discomfort due to eye dryness or minor irritations.

Administration and Dosing

The product is administered to the eye as needed. The standard dosing rule for this lubricating eye drop solution is to instill 1 or 2 drops into the affected eye(s). Since this medication is used on an as-needed basis, there are no specific timing constraints in relation to meals or formal missed-dose instructions. If an individual is following a specific schedule and misses an application, the dose should be skipped, and the individual should not use two doses at one time. The product is for external use only.

Procedural Steps

The following procedural steps ensure proper and safe use:

• Handwashing: Hands should be washed prior to use.
• Inspection: Do not use the solution if it changes color or appears cloudy.
• Instillation: Instill 1 or 2 drops into the affected eye(s).
• Contamination Avoidance: To prevent contamination, the tip of the container must not be touched to any surface, including the eye itself.
• Container Management: The cap of the multi-dose bottle must be replaced after use. The multi-dose bottle should be discarded 90 days after opening. Single-use containers (vials) must be discarded immediately once opened and should not be reused.

Administration Scope	Detail
Route of Administration	Ocular (Topical Instillation)
Dosing	Instill 1 or 2 drops in the affected eye(s)
Frequency Pattern	As needed
Regulatory Category	Over-the-Counter Drug

---

These instructions establish a protocol for ocular use, focusing on the correct instillation volume and frequency (1 or 2 drops, as needed). A key component of the use protocol involves strict anti-contamination and discard rules, which differ depending on whether the multi-dose bottle or the single-use preservative-free vials are used, ensuring the product is used in its sterile state.

Evidence for Use in Chronic Dry Eye Disease Symptoms

Research has explored the clinical evaluation of ophthalmic lubricants containing Sodium hyaluronate and Glycerin, which were used in studies exploring how symptoms change over time for individuals with chronic dry eye disease (DED). These investigations often take the form of Randomized Controlled Trials (RCTs) and Systematic Reviews that combine data from multiple clinical trials. This research examined patient-reported outcomes describing perceived discomfort, using standardized tools like the Ocular Surface Disease Index (OSDI), and objective measures such as the Tear Film Break-Up Time (TBUT) to measure the stability of the tear film.

Systematic reviews reported patterns where final symptom scores were monitored and described in participants using this type of lubricant, compared to control groups over the study period. Research highlights changes measured during the study period for objective signs, where measurements of TBUT (a marker of tear film stability) were observed to be numerically higher in some treatment groups. However, findings were mixed across studies for certain objective outcomes, such as measurements of tear volume. Comparative evidence is lacking for this specific Glycerin/Sodium hyaluronate combination against every other specific type of combination lubricant available.

---

Evidence for Use Following Eye Surgery

Research has also explored the clinical context of this lubricant class in patients reporting dry eye symptoms that arise after surgical procedures, such as cataract surgery. This evidence is often derived from meta-analyses that pool data from several smaller RCTs. These studies monitored patient-reported outcomes describing perceived discomfort and objective signs like staining scores during the healing process.

Analysis of trials reported that symptom scores were monitored and described in patients who used the lubricant during the initial, short-term (one-month) recovery phase. Research found it difficult to attribute findings solely to the lubricant, as some research included it as part of a multi-drug regimen. Follow-up durations were limited, meaning long-term effects are not fully established for this specific scenario.

---

Long-Term Studies and Research Gaps

Most of the studies that have examined this lubricant class have concentrated on short-term or intermediate-term effects, with follow-up typically limited to 12 weeks or less. Evidence related to the long-term effects on maintaining ocular surface status or managing symptom recurrence over extended periods are not fully established. Additionally, studies rarely provide detailed, separate data for specific age strata, meaning subgroup findings are uncertain for older adult populations.

Key Studies & References

1. OASIS TEARS PF PLUS PRESERVATIVE-FREE LUBRICANT EYE- glycerin solution/ drops (DailyMed label)
2. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye (2002)

Common questions about Oasis Tears Plus (FAQ)

---

Q: How long does a single application of Oasis Tears Plus usually provide relief?

According to the official product information, the drops are formulated with high-molecular-weight sodium hyaluronate. This ingredient is described as a viscoadaptive component. This property is consistent with providing extended moisture retention and comfort on the ocular surface.

---

Q: Is it normal to feel a temporary blurred vision after using the drops?

Official regulatory documents list blurred vision as one of the documented temporary side effects that may occur with this class of ophthalmic lubricant. The vision change is usually temporary and is documented as lasting for a short time after application.

---

Q: How quickly should I expect to feel the drops working after application?

The product's regulatory classification is for the temporary relief of dry eye symptoms. This suggests that the symptomatic action is usually rapid upon application to address burning and irritation.

---

Q: Is it safe to use Oasis Tears Plus while pregnant or breastfeeding (as per regulatory documents)?

Regulatory labeling requires that individuals who are pregnant or nursing must consult a health professional prior to using this product. This requirement is noted in official documentation regarding use during pregnancy and lactation.

---

Q: Why do some people experience temporary stickiness on the eyelids?

As with many viscous ophthalmic lubricants, the official adverse reaction data includes sensations such as a foreign body sensation or stickiness of eyelashes as less common, documented effects. This may be related to the product's consistency and its function as a coating agent on the eye surface.

---

Q: How often can Oasis Tears Plus typically be applied?

The official directions state to instill 1 or 2 drops in the affected eye(s) as needed for temporary relief of symptoms. The regulatory labeling does not provide a specific maximum number of times the drops can be used per day.

---

Q: Can Oasis Tears Plus be used by children, according to product labeling?

Official labeling for this product states that use in the pediatric population is not established. The official documentation also advises that the product should be kept out of reach of children.

---

Q: What should I do if I accidentally use an expired Oasis Tears Plus vial?

Official documents state that the product must be used before the expiration date marked on the container. After this date, the sterility and intended effectiveness of the preparation may not be guaranteed.

---

Q: Are there any reported interactions with oral medications or supplements?

The regulatory profile notes that because this product is administered topically to the eye, its active ingredients exhibit minimal to negligible systemic absorption. Due to this minimal exposure, formal systemic drug-drug interaction studies for oral medicines or supplements are not typically cited in the labeling.

---

Q: Can a person who has glaucoma use Oasis Tears Plus?

Regulatory documents do not list glaucoma or other systemic conditions, such as hepatic or renal impairment, as a formal contraindication for this topically administered, non-systemic product. The only absolute contraindication documented is known sensitivity or allergy to any of the product's ingredients.

---

Q: What is the difference in consistency compared to other artificial tears I've tried?

The product is formulated with high-molecular-weight Sodium hyaluronate, which is described as a viscoadaptive polymer. This chemical property means the solution is generally thicker and has a greater ability to coat and stabilize the tear film compared to non-viscous solutions.

---

Q: Is Oasis Tears Plus only for severe dry eyes, or can it be used for mild cases?

The regulatory labeling states the product is for the temporary relief of burning and irritation due to both dryness of the eye and minor irritations. This indicates a broad application for various degrees of dry eye discomfort.

---

Q: What happens if I miss an application of the drops?

Since the product is administered on an as-needed basis for symptom relief, there are no formal missed-dose instructions. The general rule for such products is to skip the missed application and not use two doses at one time.

---

Q: Can I use the drops if I have a history of ocular allergies?

The product is contraindicated (should not be used) if an individual is known to have a sensitivity or allergy to any ingredient in the product, including glycerin or sodium hyaluronate. This is the primary safety constraint regarding allergies listed in regulatory documents.

How to Store and Dispose of Oasis Tears Plus

Oasis Tears Plus must be stored strictly according to the conditions detailed in the official regulatory labeling.

Storage Conditions

Requirement	Condition
Temperature Range	Store at or below 77°F (25°C) and above 32°F (0°C).
Environmental Protection	Protect from light and freezing (Do not freeze).
Safety	Keep out of reach of children.

Handling and Disposal

As a preservative-free, single-use product, the container must not be reused and must be discarded once opened. Do not use the solution if it changes color, becomes cloudy, or if the single-use container is not intact. Use the product before the printed expiration date. If the solution is accidentally swallowed, immediately contact a Poison Control Center or seek medical help.